Microprojection matrix applicator and device

专利摘要:
microneedle applicators. an applicator for a microprojection matrix is described. in one embodiment, the applicator comprises an energy storage element. force application causes the compressed energy storage element to extend or transition from the first and second configurations, releasing stored energy to implement a fixation element in the application that is configured to house a micropojection matrix. in another embodiment, the applicator comprises an energy storage element, with two stable configurations, a first stable configuration and a second stable configuration. application of force causes the energy storage element to transition energy from the first higher stable configuration to the second lower stable configuration energy, freeing the difference in the energies of the two states to implement a fixture in the application that is configured to contain a matrix of microprojections.
公开号:BR112012028263B1
申请号:R112012028263-8
申请日:2011-05-04
公开日:2020-06-02
发明作者:Joseph C. Trautman；Joseph C Trautman；Douglas Joseph Scott Bourne；Anthony Le；Robert Wade Worsham；Parminder Singh
申请人:Corium, Inc.；
IPC主号:

专利说明:

APPLICATOR AND DEVICE FOR MICROPROJECTION MATRIX
CROSS REFERENCE FOR RELATED ORDERS
This application claims the benefit of US Provisional Application No. 61 / 331.175, filed on May 4, 2010, which is incorporated herein by reference.
TECHNICAL FIELD
The subject described in this document generally refers to the delivery of drug using microneedles or other microprojections, and more specifically to applicators for applying a microprojection matrix to the stratum corneum.
FUNDAMENTALS
Microneedle arrays were proposed as a means of delivering drugs through the skin, in the 1970s, for example, in expired U.S. Patent No. 3,964,482. Microneedle arrays can facilitate the passage of drugs through human skin and other biological membranes in circumstances where common transdermal administration is inadequate. Microneedle arrays can also be used to sample fluids found around a biological membrane, such as interstitial fluid, which is then tested for the presence of biomarkers.
In recent years, it has become more feasible to manufacture microneedle arrays in a way that makes their widespread use financially viable. U.S. Patent No. 6,451,240 discloses some methods of making microneedle arrays. If the dies are cheap enough, for example, they can be marketed as disposable devices. a
Petition 870190122917, of 11/25/2019, p. 10/20
2/57 disposable device may be preferable to a reusable one, in order to avoid the integrated problem of the device to be compromised by the previous use and to avoid the potential need to resterilize the device after each use.
In addition to cost, integrity and sterility, an additional problem with microneedle arrays is the bioavailability of the active agent. An intravenous injection delivers a precise amount of an active agent to the circulation. Subcutaneous or intramuscular injection delivers a precise amount of an active agent in the tissue, but the amount of active agent delivered to the circulation and the rate at which the active ingredient is delivered are affected by the type of surrounding tissue, circulation and, eventually, other factors . When a drug is administered orally, the resulting blood levels may vary substantially between patients, due to metabolism and other factors, but minimum therapeutic levels can be ensured for most patients, for example, because the rate of metabolism it has an upper limit and, because there is long experience with the absorption of many drugs through oral formulations. When a drug is delivered to the skin unmodified by a conventional transdermal patch, diversion of liver circulation can decrease the effect of liver metabolism on bioavailability. On the other hand, with a conventional transdermal patch, differences in skin permeability are an additional factor that leads to differences in bioavailability.
Microneedles manipulate skin permeability in
3/57 regarding the active agent. Variability in the improvement of g 11 mt: db i. i i d u u ci ci iscid ροι o i r e ΐ e n t e s applications of microneedles will result in variations in the transfer rate through the skin, the amount transferred through the skin and its bioavailability. Variability in improving skin permeability when applying a microneedle matrix can result from application to different patients. A particular concern exists, of course, if the improvement is small in populations of particular patients, so that the administration of the drug will not produce a therapeutically effective dosage (for example, adequate blood levels) in those populations. A concern may also arise, if the improvement is sometimes undesirably small in a patient, even if at other times the improvement is as expected in that patient, depending on details of how and where the microneedle matrix is applied.
A typical microneedle array comprises microneedles that project from a base with a specific thickness, which can be of any shape, for example, square, rectangular, triangular or circular. The microneedles themselves can take a variety of shapes. While a matrix could be pressed manually on the skin, it has also been proposed to use a variety of devices to attach the microneedle matrix while it is applied or to facilitate, in one way or another, the microneedle matrix application process to the skin or other biological membrane. Such devices can be generically referred to as applicators. Applicators can, for example, reduce
4/57 variations in the strength, speed, and tension of the skin, which when applied to the skin, is manually pressed onto the skin. Variations in skin strength, speed, and tension can result in variations in the improvement of permeability.
In some applications of microneedle arrays, which can be applied to the skin or other biological membrane, in order to form microchannels, then they are more or less immediately removed. In other applications, the microneedle matrix can be held in place for a long period of time. The design of the applicator can, of course, be influenced by the time that the microneedles are expected to remain in place.
Microneedle applicators comprising components that have two stable states have been described in U.S. Published Patent Application No. 2008/0183144. The existence of two stable states is a characteristic generally desired in an applicator, because the energy difference between the two stable states can allow each use of the applicator to employ a fixed amount of energy in order to cause penetration, improving reproducibility. However, a limitation of this previous approach is that the energy supplied to the microstructure matrix is limited and variable. The previous approach was dependent on the user input for energy and speed, and the variation in the application technique had a significant effect on the device's ability to increase skin permeability.
In some other prior art applicator designs, the energy storage element, such as
5/57 a spring or elastic element, can exert forces on one or more components to the applicators, causing dimensional distortion and deformation over an extended period of time. These effects are undesirable as they lead to variations in the geometry of the applicator and a loss in the elastic energy stored over time. Therefore, there is a need for an applicator that has energy storage elements that do not exert force on one or more of the applicator components.
In the use of microneedle arrays, especially when the arrays are kept in one place for an extended period of time, devices for transporting the drug substance to the skin can be employed. A very simple device, for example, can comprise a reservoir for the liquid or solid drug substance, which is kept in contact with the base, with the liquid drug substance that flows through small openings in the base or by diffusion when the drug substance it is used. Another device suitable for delivering the drug substance to the skin is described in U.S. Published Patent Application No. 2005/0094526. Rotating applicators were disclosed in U.S. Published Patent Application No. 2004/0087992. Is there any disclosure regarding the applicators, for example, in US Patents ^Nos 6,537,242, 6,743,211 and 7,087,035.
There is a need in the art for applicators and related devices suitable for use with microneedle arrays, for example, in order to help make the drug delivery process more user friendly and uniform across all patients and for applications
6/57 different to the same patient.
SHORT ΞυΜλίνι
In one aspect, an applicator for a microprojection matrix is provided. The applicator comprises an energy storage element, which has a first stable configuration and a second stable configuration, in which the application of force can cause the energy storage element to transact from the first stable configuration to the second stable configuration, and wherein the force required for the energy storage element to transition from the first stable configuration to the second stable configuration is lower than the force required for the element to transition from the second stable configuration to the first stable configuration. The applicator also comprises a drive member which can transmit an external force to the energy storage element, a microprojection holding member connected to the drive member and which is manipulated by the energy storage element when it transitions from the first configuration stable for the second stable configuration, an external cover with an opening in which the actuating member fits in a sliding way, and a skin contact member comprising a portion that can be horizontal on the skin, in which the contacting member fits the outer cover and contacts the energy storage element when it is in its first configuration.
In one embodiment, the energy storage element has an axis of symmetry and n-times symmetry
7/57 rotational to some integer n. In another embodiment, the application of element a and energy storage in the direction of its axis of symmetry causes it to transition from the first stable configuration to the second stable configuration.
In another embodiment, an applicator for a microprojection matrix comprises a housing that has a surface with an elongated opening that has platforms on opposite sides of the opening. A drive member comprising a surface on which a microprojection matrix can be connected, a generally ring-shaped surface on which an energy storage member can be placed, and a surface capable of engaging with the platforms in the opening of the enclosure and able to fit through the opening is included. An energy storage member is located between the driving member and the housing, and a skin contact area that is generally ring-shaped is attached to the housing. In one embodiment, when the drive member is coupled to the platforms at the opening, the energy storage member is compressed, and when the drive member is moved inside the opening, so that it no longer engages the platforms, the the energy storage member is released to expand, and in doing so the drive member moves.
In one embodiment, the energy storage member is in the form of a wavy spring. In other embodiments, the energy storage member has n-times an axis of rotation of symmetry between about 3 and 22, more preferably 3 and 18 or 3 and 9, and even more
8/57 preferably between 3 and 6.
In another embodiment, the drive member moves within the outer cover between a first position and a second position, where in its first position, the drive member extends from and beyond an upper surface of the outer cover,
In another embodiment, the drive member moves within the outer cover between a first position and a second position, where in its first position, the drive member is embedded within the outer cover.
In yet another embodiment, the microprojection matrix is attached to the microprojection holding member, the microprojection matrix comprises a base, and the base level of the microprojection matrix is below a contact surface with the skin of the limb. skin contact after actuation of the actuation member.
In yet another embodiment, the base level of the microprojection matrix below the skin contact surface of the skin contact member is between about 0.001 inches (0.0254 mm) to about 0.200 inches (5, 08 mm), more preferably between about 0.001 inches (0.0254 mm) to about 0.125 inches (3.175 mm), even more preferably from about 0.030 inches (0.762 mm) to about 0.090 inches (2.286 mm).
In another embodiment, the energy storage element is in a mechanical engagement relationship with the microprojection retaining member, when the energy storage element is in its first stable configuration.
9/57
In another aspect, an applicator for a matrix of υμι tudu and lornec / uo. the aprioacior comprises (a) a casing that has a surface with an elongated opening that it has. the platforms on opposite sides of the opening, (b) a drive member comprising a surface on which a microprojection matrix can be attached, a generally ring-shaped surface on which an energy storage member can be placed, and a surface capable of coupling with the platforms at the opening of the housing and capable of engaging through the opening, (c) an energy storage member located between the drive element and the housing; and (d) a skin contact zone that is generally in the form of a washer connected to the shell. When the drive element is coupled with the platforms over the opening, the energy storage element has a first stored energy force, and when the drive member is moved inside the opening, so that it no longer couples to the platforms , the energy storage member releases its stored energy and thus moves the drive member.
In one embodiment, the energy storage member, when coupled to the platforms at the opening, has a first stored energy force because it is being compressed.
In yet another aspect, an applicator is provided. The applicator comprises (a) a housing that has a first element with a central opening and a second element having a skin contact surface, (b) a driving member arranged in the central opening and which
10/57 comprises a surface on which the microproject matrix can be fixed and extending circumferentially, and (c) an energy storage member having an inner and an outer edge, and is situated inside the housing initially in a first stable configuration so that the inner edge is arranged in the groove and its outer edge is in contact with the second member. Applying force to the drive member moves the energy storage member from its first stable configuration to a second stable configuration, in which the outer edge is no longer in contact with the second member.
In one embodiment, the outer edge of the energy storage member, in its second stable configuration, is in contact with the first member.
In another embodiment, a microprojection matrix support engages the drive member, the coupling of the drive member and the microprojection matrix support defining the groove.
In yet another embodiment, the energy storage member has an axis of symmetry and rotational symmetry of n-times to an integer n, in which the application of force in the direction of the axis of symmetry causes the energy storage element transition from the first stable configuration to the second stable configuration, and where the force required for the energy storage element to transition from the first stable configuration to the second stable configuration is less than the force required for the element transition from the second stable configuration to the first
11/57 stable configuration.
In uliiud oüleu rnooa .11 ciaoe, the energy storage and storage is generally trunk-conical with grooves in the upper part of the trunk, starting from the lower part of the cone trunk, or both.
In another aspect, any of the modalities described here of the applicator further comprises a safety mechanism to prevent movement of the drive member in a direction that drives the microprojection matrix.
In one embodiment, the safety mechanism comprises a protective cover over the applicator housing. In another embodiment, the safety mechanism comprises a movable pin inserted in the drive member on an applicator.
In another aspect, a device comprising an applicator according to any of the aspects and modalities described herein and a microprojection matrix comprising an active agent is provided.
In another aspect, a method for applying a microprojection matrix to a biological barrier is provided. The method comprises providing an applicator, as described herein, the applicator including or being able to include a microprojection matrix. The applicator is placed in contact with the biological barrier, and a drive member on the applicator is activated, to initiate the movement of the energy storage member from its first stable configuration to the second stable configuration. The movement of the energy storage member induces the movement of the microprojection matrix, directly or / 5 7 indirectly, causing it to forcibly contact the biological barrier, in modalruades in which the microprojection matrix comprises a therapeutic or prophylactic agent, the method achieves administration of the agent to a subject.
Additional modalities of the present method, microprojection matrix, kit, and the like will be evident from the following description, drawings, examples and claims. As can be seen from the description above and below, each and every feature described in this document, and each and every combination of two or more of such features, is included within the scope of this description, as long as the features included in such a combination they are not mutually incompatible. In addition, any feature or combination of features can be specifically excluded from any embodiment of the present invention. Additional aspects and advantages of the present invention are presented
at description and claims to follow on Special when considered together with examples and drawings what accompany them.BRIEF DESCRIPTIONFigs. 1A-1B OF THE DRAWINGSare seen from a applicator, such as
described in this document, the applicator shown in perspective view (Fig. IA), a sectional view (Fig. 1B) and an exploded view (Fig. 1C).
Figs. 1D-1E show the applicator of fig. 1A-1C in a perspective view (FIG. 1D) and a cross-sectional view (Fig. 1E) after the actuation of its actuation member.
13/57
Figs. 1F-1T are seen in perspective of moaaiictades of elements a and energy storage for use in an applicator as described herein.
Figs. l ^r J-lV illustrate the movement of an energy storage element between its first stable configuration and its second stable configuration.
FIG. 2A illustrates schematically, with certain exaggerated dimensions for clarity, an applicator.
FIG. 2B schematically illustrates, with certain exaggerated dimensions for clarity, a quarter of the pressure member of the applicator of FIG. 2A.
Figs. 3A-3B schematically illustrate another embodiment of an applicator, in which in FIG. 3A a schematic cross-section of one half of the applicator is shown, and in fig. 3B a perspective view of a particular component is shown.
FIG. 4A shows an exploded view of another embodiment of an applicator. FIG. 4B shows a perspective view of the same applicator.
FIG. 5 represents an alternative outer member for the applicator of figs. 4A-4B.
Figs. 6A-6B illustrate a cantilever pin safety mechanism to prevent accidental positioning of an activator.
Figs. 7A-7B illustrate another embodiment of a safety mechanism to prevent accidental positioning of an activator.
Figs. 8A-8B illustrate an example of a safety ring mechanism to prevent accidental activation of a drive member in an applicator.
14/57
Figs. 9A-9C illustrate another embodiment of an o and safety mechanism, in which a protective cover is shown in the closed position (FIG. 9A) and in the open position (fig, 9B), and arranged in a location on an applicator (FIG. 9C).
Figs. 10A-10B illustrate another embodiment of a buffer-type safety mechanism.
Figs. 11A-11B are perspective views of an applicator according to yet another embodiment, in which FIG. 11 A illustrates the applicator in a configuration prior to positioning or activation by a user, and fig. 11B shows the same applicator after implantation or activation by a user.
Figs. 12A-12B are side views in cross-section of a first modality of internal components of an applicator according to the applicator of figs. 11A-11B, wherein FIG. 12A shows the applicator in a configuration prior to implantation or activation by a user, and fig. 12B shows the same applicator after implantation or activation by a user.
Figs. 13A-13B are side views in cross-section of a second modality of internal components of an applicator according to the applicator of figs. 11A-11B, where FIG, 13A shows the applicator in a configuration prior to implantation or activation by a user, and fig. 13B reveals the same applicator after implantation or activation by a user.
DETAILED DESCRIPTION
Before describing the present invention in detail, it should be understood that this invention is not limited to
15/5 ^ specific materials or device structures, which may vary, it should also be understood that the terminology used here is for the purpose of describing only particular modalities, and is not intended to be limiting.
As used in this specification and the appended claims, the singular forms one, one, and a / o include the singular and plural references unless the context clearly indicates otherwise. Thus, for example, the reference to an active ingredient includes a plurality of active ingredients, as well as a single active ingredient, the reference to a temperature includes a plurality of temperatures, as well as the single temperature, and the like.
For information about words that have multiple meanings, reference is made to English Dictionary Oxford (2nd ed. 1989) and the Dictionary McGraw-Hill Terms of Scientific and Technical (6 ed. 2002), which are incorporated herein by reference . The inclusion of such references does not claim to have all of their definitions and is necessarily applicable here, just as people with knowledge in the art would often see that a particular definition is not really applicable in the present context.
In the present application, reference is often made for convenience to the skin, such as the biological membrane that the microneedles penetrate. It will be understood by people with knowledge in the art that, in most or all cases, the same inventive principles are applied for the use of microneedles to penetrate other biological membranes, such as, for example, those that align the
16/57 inside the mouth or biological membranes, which are exposed during surgery.
In the present application reference is also made to microneedles, such as the type of microspray or microprojection that are being employed. It will be understood by persons skilled in the art that, in many cases, the same principles of the invention apply to the use of other microsilences or microprojections to penetrate the skin or other biological membranes. Other micro-projections or microprojections may include, for example, micro-blades as described in U.S. Patent No. 6,219,574 and Canadian patent application No. 2,226,718, and edge microneedles as described in US Patent No. 6,652,478.
In the discussion of the applicators of the present invention, the term down is sometimes used to describe the direction in which microsciences are pressed into the skin, and up to describe the opposite direction. However, those skilled in the art will understand that applicators can be used where the microscopes are pressed on the skin at an angle to the direction of the earth's gravity, or even in a direction contrary to that of the earth's gravity. In many applicators of the present invention, the energy to press the micro projections is provided primarily by an energy storage member and therefore efficiency is not greatly affected by the orientation in the skin in relation to the gravity of the earth.
The dimensions of the microneedles and other micro-projections for use with the applicators described here will be a function of manufacturing technology and application
17/57 needs (for example, the active agent to be delivered, if it is contained in the microprojections, etc.). In general, however, microneedles and other micro-projections used in practice can be expected to contain a length of about 20 to about 1000 microns, more preferably from about 50 to about 750 microns and more preferably from about 100 to about 500 microns. It will often be desirable for the microsciences to be long enough to penetrate through the stratum corneum layer of the skin, at some suitable point of application on the human body, for example, the thigh, hips, arms, or torso.
The term microneedle matrix for purposes here is intended to indicate a two-dimensional or three-dimensional array of microneedles. The arrangement can be regular according to a geometric repetition pattern or it can be irregular. Likewise, a microprojection matrix denotes a two-dimensional or three-dimensional array of microprojections.
In a first aspect, an applicator for microprojection matrices is provided in which the speed at the moment the microprojection matrix contacts the skin is controlled within a predetermined range. The applicator operates when a drive element is pressed with a force that is greater than a threshold. The contact speed is substantially independent of the precise force used to press the drive element. The applicator comprises an energy storage element.
In an additional aspect, a method for inserting
18/57 microprojections in a matrix of microprojections on the skin or other oioiogrca barrier and provided. The method comprises placing an applicator in contact with the barrier into which the matrix is to be inserted and operating a driving member, which forms part of the applicator with a force that is above a predetermined threshold. The speed of the microprojection matrix and the energy per microstructure at the moment of contact with the skin need to be above a threshold and can be controlled within a predetermined range.
Applicators contemplated here will commonly have two states or configurations. In the first state or configuration, the applicator has the built-in microprojection matrix. It is expected to be in the state of the applicator following manufacture and during transport and storage. In the second state or configuration, which is obtained by pressing or otherwise operating the drive element, the microprojection matrix projects modestly from the applicator.
The speed of the microprojection matrix at the moment of contact with the skin can be adjusted, for example, by varying the amount of energy stored in the energy storage element. This is done, for example, by controlling the geometric design of the energy storage element, and the properties of the material (s) from which the energy storage element (s) is made. The energy storage element can have a compressed shape, in which the degree of compression (for example, in a spatial sense) controls the amount of energy stored.
19/57
When the energy storage element is stored in the compressed form, a variety of mechanisms external to the element, but which are part of the applicator, can be employed to release the compression and allow the element to decompress and therefore release some or all your energy.
Alternatively, the energy storage element can be bistable in that it has two stable states, in which energy is stored. The two states can have different energies. The amount of energy stored can be, for example, in the range of about 0.1 J to about 10 J, or in the range of about 0.25 J to about 1 J. The energy storage element having two bistable states is highly advantageous since, in its highest energy state, the energy storage element does not exert any significant force on the applicator components, thus alleviating problems with dimensional distortion and sliding over time. Reduction of dimensional distortion and sliding leads to the maintenance of the same elastic energy stored for an extended period of time. Maintaining the same stored elastic energy over a period of time is important to have an extended shelf life of at least preferably 8 months, more preferably 12 months, and more preferably 24 months.
The speed of the microprojection matrix at the moment of contact with the skin can be, for example, within the range of 0.1 m / s to 20 m / s, or within the range of 0.5 m / s to 10 m /s. In general, the stored energy can be used to move the microprojection matrix in contact
20/57 with the skin, as well as in overcoming any force (for example, from other components of the applicator) acts on the microprojection matrix. In addition, the stored energy can be used to move other components that, according to the design of the applicator, must also move as the microprojection matrix moves towards the skin.
The speed of the microprojection matrix is preferably reproducible. For example, the standard deviation of the speed of a number of applications performed with different applicators of the same design or by different people, using the same applicator can be less than about 10% of the average speed, less than about 5%, or less than about 1%.
It may be desired that the applicator comprises one or more components, which have symmetry of rotation about an axis perpendicular to the microprojection matrix. For example, the applicator may comprise components that have n-fold rotational symmetry (symmetry in rotations of 360 / n degrees), for an integer n> 1, for example, n = 2, 3, 4, 5 or 6. To give an example, the clamp shown in fig. 3B, an applicator component described here, has 3 times rotational symmetry.
It may be desirable for the energy storage element to be in mechanical coupling relationship with the microprojection matrix or a matrix support member at all times. An alternative design, however, will allow the energy storage element not to be attached to the microprojection matrix during the stored state of the applicator, but only to contact
21/57 with the matrix or a matrix support member, during the activation process. Such contact may occur at a non-zero speed, although it is desirable that this non-zero speed is low, for example below about 0.1 cm / s, or below about 0.25 cm / s or less than about 1 cm / s.
After contacting the microneedle matrix with the skin or other barrier, there may be a modest bounce of the matrix against the skin, since the skin has elastic properties. The microneedle matrix can then set, pressed by the applicator, on the skin at a level that is modestly below the original level of the skin. The force with which the microprojection matrix is pressed on the skin can be, for example, between about 0.1 and about 10 N / cm ² . The base level of the microprojection matrix below the skin is about 0.001 inches (0.00254 cm) or more, and in other embodiments it is between about 1/16 inch (0.0625 inches or 0.159 cm), and about 3/16 inch (0.188 inch or 0.476 cm), or between about 1/16
inch (0.0625 inches or 0.159 centimeters) to fence in 1/8 inch (0.125 inches (3.175 mm) or 0.318 cm).On a common arrangement in which one device in storage power tablet is employee, The
The applicator has a primary limb, which is in contact with the skin, when the applicator is to be used. The microprojection matrix is connected to a retaining member that holds the energy storage device in compression. The retaining member is held in place by a flexible mechanism. The drive mechanism causes the flexible mechanism to be displaced or deformed
2/5 V elastically so that the retaining member is no longer repressed. The energy storage device is then released to expand or move between the first and second configurations, moving the retaining element, and the microprojection matrix is then displaced towards the skin.
Turning now to the drawings, figs. 1A-C illustrate several views of a possible arrangement of an applicator 10. The applicator comprises a skin contact element 12 which has an opening 14 in its center, and, in this embodiment, has full rotation symmetry. The skin contact element 12 is coupled to an applicator housing 16, which, in this embodiment, also has full rotation symmetry and is manufactured from a rigid material (for example, a metallic, polymeric, polymeric material of filling, or composite), which is preferably not visibly flexible during the operation of the device). It will be noted that the casing can also be semi-rigid, semi-flexible or flexible, if desired. The housing 16 has an opening 18 in the upper part, through which a drive member 20 slidably engages. As best seen in FIG. 1B, connected to a lower surface 22 of the drive member 20 there is a support 24 that has a microprojection matrix (which is not shown in FIGS. 1A1C). When the lower surface 22 and the upper surface of the support 24 are in contact, a groove 28 is defined which again has full rotation symmetry. A bistable energy storage member 28 that is approximately trunk-conical in shape has an inner edge 30 positioned within groove 26. The
3/57 energy storage of this modality is referred to here as a groove hollow, described in more detail hereinafter.
Figs. 1D-1E illustrate the applicator after actuation of the actuation member 20. The housing 16 and its lower part with the skin contact element 12, are shown in FIG. 1D, in which the actuating element 20 is not visible because it has been pressed and is fully retained within the housing. Extending slightly beyond the skin contact element 12 is the lower surface of the drive element on which a microprojection matrix is made. FIG. 1E is a cross-sectional view taken along line A-A in fig. 1 D, where the driving member contained within the housing is visible. Also visible is the configuration of the grooved spring element 28 where its inner edge 30 is in a second position in relation to its position before actuation, as shown in Fig. 1B. Specifically, the inner edge 30 of the energy storage member is in a horizontal plane that approaches or approaches the horizontal plane of the grooved spring edge before use. This transition and inversion of the spring element is described in more detail below.
The materials from which the applicator components are manufactured can be selected from a wide variety known to a person skilled in the art. For example, a polymeric filling material is suitable for the manufacture of the outer layer, the driving member and / or the retaining member
4/57 microprojection. A person skilled in the art will understand the various properties of the material to be considered when choosing a suitable material for each component.
Figs. 1F-1G are seen in perspective of two different modalities of energy storage members for use in an applicator as described herein, as shown in fig. 1A-1E. The energy storage member 40 of FIG. 1F is substantially in the shape of a ring and, more specifically, approximately a truncated cone shape. Inner edge of the member 42 of the member and outer edge 44 of the member define a region of the disc 48. Upper grooves, such as upper grooves 48, 50, are cut in the region of the disc. Lower grooves, 15 such as lower grooves 52, 54, are cut from the disc region from the outer edge 44. The upper and lower grooves are offset from each other, so that the lower groove is positioned between the adjacent upper grooves, and vice versa. The grooves are used to reduce the tension of the material during its movement between its first and second stable configurations, as will be described.
FIG. 1G illustrates an alternative modality of a
storage member energy 60. 0 member in 25 energy storage 60 gives FIG. 1G it is substantially in shape in an ring and> more
specifically, a trunk-conical shape. The inner edge of the member and outer edge 84 of the member define a region of the disc 68. A plurality of grooves, such as grooves 88, 70, are cut in the region of the disc. At
5/57 grooves serve to reduce the tension of the material during its movement between its first and second stable configurations, as will be described.
The energy storage members of the present applicator are movable between the first and second stable configurations, in the first stable configuration, the inner edge (or margin) of the energy storage member is in a horizontal foreground 72 and the outer edge ( or margin) of the energy storage member is in a second horizontal plane 74, which is lower than the first horizontal plane, as shown in Figs. 1U-1V. Applying force to the energy storage member causes the movement of a second stable configuration, in which the inner edge of the energy storage member approaches the horizontal background and the outer edge of the energy storage member approaches horizontal foreground. In a sense, the relative positions of the inner edge and inverted outer edge as the member transitions from a first to a second stable configuration, and back. In one embodiment, the force to move from the first stable configuration to the second stable configuration is less than the force required to move the member from the second stable configuration to the first stable configuration. In one embodiment, a force at least 10% greater, preferably 20% greater, even more preferably 30% greater is required for the transition of the member from its second stable configuration to its first stable configuration.
In a preferred embodiment, the storage member
26/57 of energy, as an axis of symmetry with a symmetry of tuLdÇdo o and laughs times for n, where n an integer of 1, 2, 3, 4, 5, 8, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In a preferred embodiment, n is a number between 3 and 18, preferably between 3 and 12, even more preferably between 3 and 9. As an example , the grooved spring mode of fig. 1G has an axis of symmetry with a 9 times rotational symmetry. The energy storage member is stable in both its first and second configurations, when stable it wants the member not to make the transition between the first and second configurations except by applying external force. As noted above, in a preferred embodiment, the force to move from a second configuration to a first configuration is different, for example, greater than the force required to move from a first configuration to a second configuration.
A person skilled in the art will appreciate the wide variety of energy storage members that would be suitable for use, and the examples are illustrated in FIGS. 1H1T. The modalities shown, with the exception of Figs. IR and IS, has an axis of symmetry. Several modalities have a 9-fold rotational symmetry, for example, the modalities of Figs. IK and 1L. Other modalities have a 6-fold rotational symmetry, for example, the modalities of FIG. 1H, 1J, IM and 1T. It should be understood that other similar shapes, including, but not limited to, other axysymmetric shapes, can be used to create an energy storage member, with two stable configurations. Additionally, non-symmetrical shapes can
7/57 can be used to create a storage element of en-_yici, products with stable figures. It is also to be understood that the presence or absence, the size, shape, configuration and any grooves or indentations in the energy storage member can be changed to allow the energy storage member to have two stable configurations. It is also to be understood that the energy storage member may comprise a plurality of energy storage members, which may or may not be identical in size, shape, and material. The use of a plurality of energy storage members is useful to allow changing the applicator speed, energy, activation force, or other performance characteristics in a way that cannot be achieved with a single energy storage member.
In operation, and with reference again to Figs. 1A-1E, an applicator comprising an energy storage element is placed in contact with the skin in such a way that the skin contact element 12 is directly over the stratum corneum and, optionally, adheres the skin by means of adhesive placed on the element 12. The energy storage element is in a first stable configuration, and is movable to a second stable configuration by applying force. Drive element 20 is pressed downward in the direction of arrow 32. This causes the drive member 20 to move downwardly, engaging the inner edge 30 of the energy storage member 28, and applying the force necessary to move the energy storage member for your second configuration
28/57 stable, in which the inner edge 30 of the limb approaches the horizontal plane in Ler ιυι merit and begins at the outer rim of the limb (for example, FIGS. 1E-1F). As a result of the movement of the energy storage element, a micro array in contact with the support 24 forcibly comes into contact with the skin.
The energy storage member inversion process can be quite fast, appearing for example instantaneous to the human eye. It can last, for example, no more than about 10 ms, no more than about 30 ms, or more than 100 ms, or no more than a second. The shape assumed by the energy storage member following the inversion may be a reflection of the original shape on a plane.
The material from which the energy storage member is manufactured is variable, and a person skilled in the art will appreciate that it is selected based on considerations of the various designs, including the desired storage life and application of force, which, of course, it will also depend on the configuration of the element. Examples of materials include metals, alloys, plastics, and specific examples include stainless steel and thermoplastics.
FIG. 2A shows schematically, in cross section, with certain exaggerated dimensions for emphasis, another modality of an applicator, before activation. Applicator 100 comprises three main members, an actuator 102, a casing 104, and a pressure member 106. Casing 104 comprises a contoured distal edge 108 for contact with skin 110. Casing 104 also has at least two projections that extend to
29/57 from its inner circumferential surface, such as the joint / 112, 11o. for other modalities, the number of projections is 3, 4, 5, 8, 7, 8 or more. Each projection engages with a corresponding projection extending from the pressure member 106, where FIG. 2 shows the corresponding projection 116 coupling with the projection 112. Collectively the projections support the pressure member 106 and resist the force of a spring 118 tending to push the pressure member 106 down. Member 106 has a flat base surface 120 on which a microprojection matrix 122 is affixable or affixed.
In order to cause the member 106 and the attached microprojection matrix 122 to be directed on the skin 110, it is necessary to displace the member 106 from the projections, such as 112 and 114. In order to do this, the driving member 102 is used. It contains, for each of the projections, such as 112 and 114, a rod, just like the rods 124, 126. The rod, by pressing on the corresponding projections, causes the projection to flex inwards and escape contact with its projection corresponding, such as corresponding projections 112, 114. Having moved through these projections, member 106 is no longer supported by them, and spring 118 is free to release its energy in order to move member 106 downwards.
The structure of the member 106 is explained further by fig. 2B, which schematically shows a room of member 106. It is observed that this room has a base 130, a wall 132, a central column 134 and a projection 136, which is designed to couple with a projection on the
30/57 applicator housing, such as projection 112 seen in the
In figs. 2A-2B, as indicated above, the dimensions are exaggerated for reasons of clarity. In reality, the projections on the members 104 and 106 may be smaller than shown in the figures, so as not to require such great inward flexion when the driving member 102 is pressed downward. All three members 102, 104 and 106 would be expected to be composed primarily of flexible polymers or rigid polymers (including reinforced polymers). Possible materials include polycarbonate, polyetheretherketone (PEEK), polyethylene, polypropylene, polyethylene terephthalate, or other polymeric material. Fillers added to the polymer during manufacture may include glass fibers, aramid fibers, Keviar fibers, metallic fibers, carbon fibers or other polymeric filler material. These fillers serve the purpose of transporting additional loads within the polymeric matrix so that the mechanical load experienced by the polymer in the parts of the applicator is distributed between the polymer itself and the filler material. The use of filler materials within the polymer reduces dimensional distortion in the applicator parts if they experience any mechanical load. The polymer and filler materials also minimize deformation due to the lower force experienced by the polymer itself. The reduction of dimensional distortion and deformation leads to the maintenance of the same elastic energy stored for an extended period of time. Maintain the same elastic energy
31/57 stored over a period of time it is important for Lcx to have a long silver life, preferably at least 8 months, more preferably 12 months, and most preferably 24 months. These materials and features described here can also be used for other parts of the applicator to increase mechanical strength and
stability, and reduce d istortion dimensional and deformation.Many variations in FIG. 2A are possible. Per example, the number n of projections such as 112 and 114 in back from periphery internal member 104 may to be
miscellaneous. They would generally be expected to be positioned in positions with 360 / n degrees of separation, but it may be desired to space them more closely in some cases, for example, with four projections at 0 degrees, 80 degrees, 180 degrees and 260 degrees.
The skin contact edge 108 of housing 104 may be provided with a skirt so that the area that contacts the skin is more extensive. The edge in contact with the skin can be provided with an adhesive, which in turn could, when stored, be conveniently covered by an optional release liner.
In the device of Figs. 2A-2B, the energy required for the drive is needed to flex projections inward, such as projections 116 (FIG. 2A} or 136 (FIG. 2B) of member 106. This energy depends on its precise dimensions and the characteristics of the material (for example, Young's modulus) of the material they are made from. If this pressure was low enough that inadvertent triggering was a possibility,
2/5 7 it may be desirable to place a kind of spring or similar object between the actuation member and the pressure member, so that an energy necessary to deform this object must be supplied before the actuation can occur. The use of such an object allows the user's input strength to be set at a level suitable for the target population, without imposing limitations
regarding the stored energy in the used spring for boost The microneedle matrix. In other variants in the drawing of Fig. 2A-2B is possible use the features in addition to or
different from the projections to support a pressure member and the spring in place before actuation. Such a design is shown in figs. 3A-3B.
In fig. 3A, which is a schematic cross-section, there is a member 164 that makes contact with the skin. Coupled with the member 164 is a clamp 168, which is also described in perspective in fig. 3B. Clamp 168 has a number of exterior projections, such as projection 172. In the embodiment shown, there are three such exterior projections. These outer projections can generally flex in an approximately radial direction towards the center of the clamp 168. These outer projections fit into openings in the member 164 as shown in FIG. 3A. Underneath member 164 is an additional member 166 that supports a microprojection matrix (which is not shown in the figure). Between members 164 and 166 is a spring 170. Spring 170 serves as an energy storage member. It tends to push member 166 down. However, it is constrained by projections 172 of the
33/57 clamp 168.
In cwiLduj with clamp i oo na a driving member 160. It has openings like 162, one for each of the outer projections, like 72. The lower portions of these openings, like 162 have a surface against which the projections like 172 are pressed during storage. However, when the driving member 160 is pushed down, eventually, projections such as 172 are enabled to flex outward, releasing the member 166 and allowing the spring 170 to push the member 166 downwards towards the skin.
The springs of different types (not shown in fig. 3A) can be used to establish the minimum force that is necessary to push down the member 160 and activate the applicator. Such springs can, for example, be placed between the upper surface of the member 164 and the lower (inner) surface of the drive member 160.
Clamp 168 can be made of metal, while the rest of the applicator is made of suitable polymers. When fabricating the metal clamp, the vertical wall of the enclosure can be made thinner, a thick section on the wall is not necessary to avoid deformation. As can be seen from the description above, projections 172 in this embodiment extend further outward than the position shown in FIG. 3A, so that a force is needed to push them enough to fit snugly to the bottom of opening 162 in housing 160, as shown in FIG. 3A.
Figs. 4A-4B schematically reveal another
4/57 modality of applicator 180, shown fully assembled
F1C. 'A c cr. vI ^ lq expioaioa at tig. 4B. An outer shell 182 is separated by an energy storage member 183 from a microprojection bearing member 184 that contains a microprojection matrix (not shown in the figure). In this embodiment, the energy storage member is in the form of a wave spring, as illustrated in FIG. 4B. A wave spring is more preferable in some embodiments than other types of compression springs, due to its small size when compressed, which is valuable for a disposable device. It is to be understood that other compression springs are also suitable and the applicator of the present modality is not limited to a wave spring. In storage, microprojection support member 184 is held in place by two platforms in housing 182, such as platform 196, against which a projection member, such as members 185, 187 on member 184, engages. When it is desired to activate the device, a user twists the limb 184 (for example, gripping the projection limbs 185, 187 with his thumb and index finger), so that it no longer rests on the platforms and is retained by them. When this twist occurs, member 184 moves downward, pressing the microprojections against the skin.
The applicator of figs. 4A-4B is also supplied with a set of components for adapting to the skin, and in this case, an adapter 190, a pressure ring 186, and an extender 188. This extender has the same function as the flange that is designed for seen in fig. 3A, as part of member 164. In addition, FIG. 4A shows a sticker 192 and
35/57 a release film 194. These types of components dem the CCR ^ _c & aunexao used with other applicators described herein. The applicator of figs. 4A-4B also includes an optional safety feature, in this embodiment, in the form of a pin 197 which is removably inserted through a cavity in the microprojection support member 184 prior to use. To allow the applicator to be triggered, a user pulls pin 197 from its holding position, as shown in FIG. 4A to allow a user to activate the applicator by the previously described twisting motion.
In an alternative embodiment of the applicators of Figs. 4A-4B, the applicator extender 188 may have a trunk-conical shape, rather than a flat shape.
In another embodiment of the applicator of figs. 4A-4B, the wrapping member may be provided with its own projection outward for adaptation to the skin, as shown in FIG. 5. In FIG. 5, the housing 220 comprises a base surface 222 with a projection 224 designed for contact with the skin when in use. An outer portion 226 of the projection 224 is less thick than an inner portion 228. Reinforcing elements, such as element 230, are provided. In the same way in Figs. 4A-4B, there is an elongated opening 232 at the top of housing 220, where the opening comprises two platforms, such as platform 234, against which the microprojection support member presses when the applicator is in storage.
A merit feature for applicators is the
36/57 skin penetration efficiency achieved with a partlculdi microprojection matrix. an exemplary uesue for skin penetration efficiency requires placing the microagu1 has matrix in a cadaver skin test sample, inserting the matrix, the applicator under test, and removing the matrix after a period of time. At this point, the percentage of openings in the skin sample that are considered adequate to allow material to be transported can be taken as a figure of merit. One material that can be used to test the suitability of transport is Indian ink. It is desirable that at least about 80%, preferably at least about 90%, and more preferably at least about 95% of the openings in the skin allow for adequate material transport.
The applicators described above may optionally include a safety or closing mechanism to prevent unintentional activation of the applicator and consequent implantation of the microneedle matrix. Various modalities of a security mechanism are now described.
In a first embodiment, a pin or separator is used to prevent accidental activation of the applicator. As an example, Figs. 6A-6B illustrate a cantilevered pin safety mechanism, in which a retaining member 300 is dimensioned to press fit into the applicator housing. The retaining member 300 is shown in FIG. 6A positioned over an applicator housing, and is shown alone in an enlarged side view in FIG. 6B. One or more pins, such as pin 302, on the retaining member fit into a groove in the
7/57 an applicator drive member, preventing the implantation · - · d-member and acj onamment. Rotating the retaining member clockwise or counterclockwise, by pressing the ring 304, releases the pin from the retaining groove to allow the drive member to be implanted.
Another example of a pin-type safety mechanism is shown in Figs. 7A-7B. Applicator 310 comprises a housing 312 and a driving member 314 movably inserted into an opening in housing 312. A groove 316 is formed in the driving member 314 in a position where the groove is in mobile coupling, with a pin 318. When the pin is fully engaged in the groove, the drive member 314 is in a locked position. A twisting motion of the housing or the drive member unlocks the pin and the groove, so that the drive member can be implanted.
FIGS. 8A-8B illustrate other examples of safety ring mechanisms, where in FIG. 8A a cantilever pressure ring 320 is movable to displace a pin 322 that locks a drive member 324 in place. FIG. 8B shows a twist ring or snap ring 326, which interferes with the movement of the driving member 328. Removing the twist ring through the twist until it breaks free the safety mechanism and allows the applicator to be activated.
In a second embodiment, a safety mechanism in the form of a protective cover is provided to prevent the inadvertent activation of an applicator comprising a microneedle array. An example is given in figs. 9A
38/57
9B, where cover 350 is shown in a closed position (PIG. Oz ' _c pjalçàu abei La ír iG. 9B). The cover 350 comprises a retaining member 352 and a cup member 354 connected to the retaining member by a flexible connecting member 356. Splinters or hooks extend from the retaining member to secure the cover to an applicator, as shown in FIG. 9B. The cup member protects a drive member in the applicator, preventing inadvertent application of force to the drive member, as well as consequent implantation of the microneedle matrix.
Figs. 10A-10B illustrate another modality of a cover-type safety mechanism, where a shell cover 360 fits perfectly around the outer periphery of an applicator, preventing access to the applicator's driving member. Removing the shell cover exposes the drive member, making it available for use.
In another embodiment, the applicator described here was designed to avoid unintentional activation of the applicator and consequent implantation of the microneedle matrix according to the drawing shown in figs. 11A-11B. FIG. 11A reveals an applicator 400, in a configuration before implantation or activation by a user. FIG. 11B reveals the same applicator after implantation or activation by a user. Applicator 400 comprises a rigid housing 402 composed of a first member 404 and a second member 406. In another embodiment, the housing is semi-rigid, semi-flexible, or flexible. First and second members are configured to mate with each other in order to mate together
9/57 in a safety configuration, such as by a snap-fit mechanism or an insertable steel / groove mechanism (see, for example, in FIG. 12A). First member or upper housing member 404 has a central opening 408 into which a drive member 410 slidably fits. The second skin contact member or member 406 is hollow or open, to receive the actuating member by activating the applicator, as can be seen in FIG. 11B. Before activating the application (Fig. 11A), the plane of the top surface of the actuation member, indicated by dashed lines 412 in FIG. 11A, is coplanar or slightly under / below the plane of the upper edge of the first member 404 of housing 402, indicated by dashed line 414 in figs. 12A-12B, which are seen in cross-section of an exemplary applicator. In this configuration, the upper outer surface of the drive member is coplanar with the upper surface of the housing, so that the drive member is nested within the housing prior to its activation. After actuation of the actuation member, in which the actuation member is implanted to a second position, the actuation member is pressed into the housing and the upper surface of the actuation member approaches a plane defined by an upper margin of the second member of housing 406, denoted by the dashed line 416 in figs. 12A-12B. As can be appreciated, the design, in which the drive member is nested in the housing prior to activation (for example, the drive member does not extend out of the housing) prevents inadvertent implantation of the applicator.
0/57
The internal components of an applicator, in which the external upper part of the actuator tics flush with the highest surface (proximal to the skin contact surface of the enclosure) of the enclosure may vary, and two modes are shown in Figs. 12A-12B and in Figs. 13A-13B, wherein the elements similar with respect to Figs. 11A-11B are given as numeric identifiers despite FIGS. 12A-12B and Figs. 13A-13B are different modalities. In FIGS. 12A12B, applicator 400 is shown in a cross-sectional side view. The first member 404 of the housing 402 has an upper margin 420 that defines an upper plane of the applicator, the upper plane denoted by the dashed line 414. The drive member 410 is movably positioned in the housing, movable between a first and a second position , in which in its first position the upper surface of the driving member, indicated by the plane indicated by the dashed line 412, is coplanar with the upper plane of the applicator, or is slightly smaller than the upper plane of the applicator, as can be seen in FIG. 12A. After the application of a force, represented by the arrow 422, by a user, the actuating member moves to its second position, for implantation in a user's skin of a microneedle matrix (not shown) positioned on a support member 424 engaged with the drive member. In its second implanted position, the upper surface of the drive member approaches, contacts or moves beyond, a plane defined by an upper margin of the second housing member 406, in the plane indicated by the dashed line
41/57
416.
Con. leieiêiicio cuiiL ijiuaaa as MÜS. 12A-12B, the drive member 410 travels from its first position to its second position along a plurality of guide fins, such as fins 426, 428. One groove for each guide fin, such as groove 430, is arranged on the drive member. Grooves or grooves are similarly provided in the first and second elements of the enclosure to secure each guide fin to the applicator. The plurality of guide fins guides the plunger of the driving member with respect to the housing to maintain alignment during activation of the device. Each guide fin is sized sufficiently to avoid sharp edges and the edges can be curved with a radius of curvature to ensure no sharp edges. It is also desirable that each guide fin has a horizontal axis of symmetry which allows its insertion into the housing in both directions.
Figs. 13A-13B are side views in cross-section of another embodiment of the applicator of figs. 11A-11B, wherein FIG. 13A shows the applicator prior to activation and FIG. 13B shows the applicator after its activation. In this embodiment, the applicator prior to activation has a driving member 410, which is embedded within the housing, as is evident from the fact that the upper surface of the driving member is lower or is under the upper margin of the first member enclosure 404, as illustrated by the respective dashed lines 412 (corresponding to the plane defined by the upper surface of the drive member)
2/57 and 414 (corresponding to the plane defined by the plane defined by the upper margin to the first housing member). As seen in FIG. 13B, activation of the actuation member by applying force moves the actuation member to its second position, where the upper surface of the actuation member is closest (in relation to the upper surface of the actuation member in its first position ) to the upper margin 407 of the second member of housing 406, indicated by dashed lines 416. The drive member moves from its first position to its second position along a plurality of guide posts, such as posts 432, 434 The guide posts extend from the first member of the enclosure to the second member of the enclosure and are attached to each member. The outer circumference of the drive member contacts each of the guide posts, which serves to guide the drive member in relation to the housing during movement of the drive member.
Figs. 12A-12B and 13A-13B also illustrate the energy storage element 436 positioned with the applicator. As discussed in detail above, the energy storage element moves from a first position to a second position, by applying force to the drive member. Movement from its first to its second position, occurs only by applying sufficient force, and results in an inversion of the element. The element is stable in both its first and second positions, in that it does not move relative to itself between positions, but requires the application of force to move from its first to
3/57 to its second position, and from its second position it went to its first position. In a preferred embodiment, the force required to move the element from its second to its first position is less than the force required to move the element from its first to its second position. In the absence of force application, the element cannot return to its first position after the device is activated. Before activation of the applicator device, the energy storage element contacts the second housing element that is in contact with the skin, and after activation, the energy storage element is in contact with the first housing member (also referred to as an external cover). The activation of the drive member releases the energy stored in the energy storage element, the release energy acting on the microprojection support member in contact with the drive member.
Methods of Use
In another aspect, a method for administering an active agent to a subject is provided. The method comprises providing a microprojection matrix in conjunction with any of the applicators described herein, the microprojection matrix comprising an active agent. The agent is delivered transdermally by activating the applicator, to implant the microprojection matrix in contact with the skin, or more generally a membrane or body surface, of a subject. The active agent to be administered can be one or more of any of the active agents known in the art, and include broad classes of compounds, such as, by way of illustration and
4/57 not limiting: analleptic agents; analgesic agents, to be used and to be used. anti-cancer drugs, including antineoplastic, anticholinergic drugs; anticonvulsants; antidepressants, antidiabetic agents, antidiarrheal agents; antihelmintics; antihistamines, antihypertensive agents, antihyperlipidemic agents; anti-infectious agents, such as antibiotics, antifungal agents, antiviral agents and bacteriostatic and bactericidal compounds, anti-inflammatory agents, anti-migraine preparations; anti-nauseating agents; antiparkinsonian drugs; antipruritic agents; antipsychotics; antipyretics; antispasmodics; anti-tuberculosis agents, anti-ulcer agents; anxiolytics;
Appetite suppressants; drugs for attention deficit hyperactivity disorder and attention deficit disorder; cardiovascular preparations, including calcium channel blockers, antianginal agents, central nervous system agents, beta-blockers and antiarrhythmic agents, caustic agents; central nervous system stimulants; cough and cold preparations, including decongestants, cytokines, diuretics, genetic materials; phytotherapics; hormonolytics; hypnotics, hypoglycemic agents, immunosuppressants, keratolytic agents; leukotriene inhibitors, mitotic inhibitors, muscle relaxants; narcotic antagonists; nicotine, nutritional agents, such as vitamins, essential amino acids and fatty acids: ophthalmic drugs, such as antiglaucoma agents, pain relieving agents, such as anesthetic agents; parasympatholytics; peptide drugs;
5/57 proteolytic enzymes, psychostimulants, respiratory drugs, including antiasthmatic agents, sedatives; steroids, including progestogens, estrogens, corticosteroids, androgens and aluminizing agents, smoking cessation agents; sympathomimetics; tissue curing reinforcing agents; tranquilizers; vasodilators including coronary, peripheral and cerebral in general; vesiculating agent, and their combinations.
In preferred embodiments is a protein or a peptide. In another embodiment, the agent is a vaccine. Example 1 below describes the administration of the human parathyroid hormone to pig skin in vitro. Examples 2-4 detail the administration of the human parathyroid hormone to humans. Additional details of the administration of the human parathyroid hormone to humans using a microprojection matrix, including detailed pharmacokinetic analysis, are provided in provisional application No. 61 / 331,226, filed on May 4, 2010; all contents of this co-filed patent application are hereby incorporated by reference. Additional examples of peptides and proteins that can be used with microneedle arrays are oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone, follicle-stimulating hormone, luliberin or luteinizing hormone-releasing hormone (LHRH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, encephalins, endorphins, chiotorphine, taftsin, thymopoietin, thymosine, thymostimulin, factor
6/57 humoral thymic, serum thymic factor, necrosis factor ^ uiiioiul, esi ..... 'colony-mimicking, motilma, bombesin, dynorphin, neurotensin, cerulein, bradykinin, urokinase, kallikrein, antagonists and substance analogues P, angiotensin II, nerve growth factor, blood clotting factors VII and IX, lysozyme chloride, renin, bradykinin, thyrocidine, gramicidins, growth hormones, melanocyte stimulating hormone, thyroid hormone releasing hormone, stimulating hormone thyroid, pancreozimine, cholecystokinin, human placental lactogen, human chorionic gonadotropin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, platelet-derived growth factor, growth hormone releasing factor, the morphogenic protein of bone, and synthetic analogs and modifications and fragments thereof pharmacologically active. Peptide drugs also include synthetic LHRH analogs, for example, buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide (leuprorelin), lutrelin, nafarelin, triptorelin, and pharmacologically active salts thereof. Administration of oligonucleotides is also contemplated, and include DNA and RNA, other naturally occurring oligonucleotides, unnatural oligonucleotides, and any combinations and / or fragments thereof. Therapeutic antibodies include Orthocione OKT3 (muromonab CD3), ReoPro (abciximab), Rituxan (rituximab), Zenapax (daclizumab), Remicade (infliximab), Simulect (basiliximab), Synagis (palivizurnab), Herceptina
47/57 (trastuzumab), Mylotarg (gemtuzumab ozogamycin), CroFab, bigiFab, campain (alemtuzumaoj, and Zevalin (britumomao tiuxetan).
It is to be understood that, while the object has been described in conjunction with the specific preferred modalities of the same, the previous description is intended to illustrate and not to limit it in scope. Other aspects, advantages and modifications will be evident to those skilled in the art to which the object belongs.
All patents, patent applications and publications mentioned herein are hereby incorporated by reference in their entirety. However, in the event that a patent, patent application, or publication containing explicit definitions is incorporated by reference, the explicit definitions should be understood as applicable to the incorporated patent, patent application, or publication in which they are found, and not separately. remainder of the text of this application, in particular in the claims of this application.
EXAMPLES
The following examples are put forward in order to provide those persons of ordinary skill in the art with a full disclosure and description of how to make and use the object described here, and it is not intended to be limiting within the scope of the object. Unless otherwise stated, the parts are parts by weight, the temperature is ⁰ C and the pressure is atmospheric or close to it.
EXAMPLE 1
COMPARATIVE APPLICATOR TESTS
Three slotted spring applicators named Bl, B2 and B3, similar to those shown in Figs. 1A-1F, were
8/5 7 compared to an applicator named A of the type II illustration in the rigs. 4A-4M for the efficiency of penetration into the skin and the ability to deliver hPTH (1-34) (a 1-34 fragment of the human parathyroid hormone, also referred to as teriparaptide, when produced recombinantly). Bl, B2 and B3 applicators differed in the exact characteristics of the grooved spring energy storage element (dimensions and materials). The BI applicator was 0.012 inches (0.3048 mm) thick in stainless steel, Applicator B2 was 0.0155 inches (0.3937 mm) thick and made of 17-7 stainless steel, and Applicator B3 had 0 , 0155 inches (0.3937 mm) thick and is made of 301 stainless steel. BI grooved springs somehow had longer notches on the outside in relation to grooved springs B2 and B3.
Microprojection matrices were manufactured from Dextran-70 and containing hPTH (1-34), as described in US Publication No. 2008-0269885. The hPTH (134) sequence used was as follows:
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-LysHis-Leu-Asn-Ser-Met-Glu-Arg-Vai-Glu-Trp-Leu-Arg- Lys-LysLeu-Gln-Asp-Val-His-Asn-Phe-OH (SEQ ID NO: 1)
The microneedles were pyramids with 4 faces spaced 200 pm, microneedle height 250 pm, and an 11 mm diameter matrix, with 2742 microneedles per matrix.
The test was carried out with smooth pig skin softened on a polyurethane foam support. The apparent dose delivered was determined by analyzing the residual amount of hPTH (1-34) in the matrices and on the skin. The
49/57 results are shown in the table.
Apparent dose% of delivery efficiency Device ID Rep #:% SPE pgMiddle SDOR! % THE Rep 1 94.3 32.4 32.0 0.6 86.4 85 2 1.7Rep 2 98.9 31.5 84.0 B1 Rep 1 83.3 18.9 23.0 5.7 50.4 61.3 15.1Rep 2 90.4 17.4 46.4 Rep 3 96.9 26 7 71.2 Rep 4 ...... 93.7 28.9 77.1 E52 ......... Rep1_ 99.9 18.5 27.7 6.2 49.3 73.7 16.4 ..... Rep 2 101.1 30.2 I 80.5 Rep 3 100 30.0 80.0 Rep 4 99.5 31.9 85.1ί B3 ..... Rep 1 92.9 8.9 19.3 8.6 23 7 51.3 22.9 IRep 2 100.8 27.0 72.0 Rep 3 94.8 15.5 41.3 —Γττττ --- Rep 4 96.4 25.6 68.3
^X SPE = skin penetration efficiency
Skin penetration efficiency (SPE) is estimated by counting the number of holes in the microneedle in relation to the region of the skin to the number of microneedles in the matrix used to treat the skin.
It is believed that certain weaker results for SPE, such as the first replication of applicator Bl, may be due to a possible error in installing the upside-down grooved spring in the plastic housing.
EXAMPLE 2
PREPARATION OF A TWO-LAYER MICROPROJECTION MATRIX
CONTAINING HUMAN PARATHYROID HORMONE (HPTH (1-34))
A microprojection matrix containing a therapeutically effective amount of hPTH (1-34) (32 pgrams) was prepared for use in a Phase I clinical study as follows.
First, in the general description of the characteristics of the microprojection matrix, the micro-projections of the matrix can be characterized in general as comprising a layer of DIT {drug in the
50/57 tip) and a support layer. The DIT layer includes hPTH (1 ~ 34) in a water-soluble matrix. The hPTH (1-34) sequence used is as follows:
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-LysHis-Leu-Asn-Ser-Met-Glu-Arg-Vai-Glu-Trp-Leu-Arg- Lys-LysLeu-Gln-Asp-Va1-His-Asn-Phe-OH (SEQ ID NO: 1)
The tip of the microprojections is also referred to here as the layer at the bottom of the tips or microscopes (i.e., close to the skin when placed on the skin), also referred to here as the end portion which is distal to the base of the matrix) . The support layer referred to in some of these examples encompasses both the upper part of the micro-projections near the base of the matrix, as well as the base itself, where the base is the portion of the matrix that supports the tips. The support layer comprises a biocompatible water-insoluble matrix. In the instant matrix device, the material at the top of the micro-projections is the same as the base material itself, so the formulation of the water-insoluble soluble matrix is applied as a single layer to fill the mold on top of the DIT layer .
The DIT layer of the microstructure matrix dissolves in the skin and contains the components shown in Table 2-1. Acetate was the counterion in the pharmacological substance hPTH (1-34).
51/57
Table ropiposition rh layer d <= * drug in the TDS tip dehPTW1-34)% w / w (da
Quantity Matrix range
Name Chemical name of ingredient microstructure) ^commercial (yg / unit) (pg) un age)
hPiH (1-34) humanof1-34 Parathyroid hormone) 321 ....... 25.6- 38.4 12.0Dextran molecular weight of Dextran 70,000 Dalton 160.0 128 0 - 192 0 58.6 So idol, NI Sorbitol 54.9 64.0 - 96.C 21.9 Histidine L- Histidine 0.14 0.11-0.17 0.1 Histidine HC1 L-histidine hydrochloride 0.73 0.58-0 88 03 AT Acetate 25 20-3.0 1.0 Total250 27100.0
The support portion or layer of the matrix was composed of poly (DL-lactide-co-glycolide), 75:25, terminated in ester (trademark; LACTEL®).
The ingredients that form the tip portion of the formulation (ie, the DIT formulation) were dissolved in water, melted, and dried in a silicone mold that contains microstructure cavities to form the drug structures at the tips (DST) . The water-insoluble biocompatible polymer, poly (DL-lactide-co-glycolide), 75:25, was dissolved in acetonitrile, to provide the support formulation which was then coated on top of the DIT layer in the silicone mold, and, then dry. The solvent was removed from the support (upper proximal portion of the base, and base) during processing and was limited to a level below the amounts recommended in the guidelines of the
ICH.
52/57
EXAMPLE 3
PREPARATION OF A TRANSDERMAL DELIVERY DEVICE (TDS) CONTAINING A MICROPROJECTION MATRIX CONTAINING HUMAN PARATHYROID HORMONE (hPTH ¢ 1-34)) The product of the transdermal / microneedle delivery system (sometimes abbreviated here TDS) was collected and contained the microprojection matrix described above in Example 2. The product was designed to deliver a systemic dose of hPTH (1-34) through the barrier layer of the stratum corneum of the skin using a microstructure matrix. The final product TDS was formed by the integration of two components, a plunger matrix set containing medicated product and an applicator set, in which these two items were packaged separately and integrated in the clinical location (see Example 4 below for clinical data).
The microprojection matrix contained in the embolomatrix set has an 11 mm diameter of about 2,700 micro arranged in a hexagonal pattern. The matrix plunger assembly consists of the microprojection matrix assembled for a matrix support member, in this case, as a plastic plunger with an adhesive laminate. The matrix plunger set was packaged inside a protective wrapper and formed a bag in a dry nitrogen environment.
The applicator set comprises a plastic wrap or cover with skin contact adhesive and a release liner, an energy storage member (in this case, a metal spring) to provide the energy needed to accelerate the plunger-matrix assembly , and elements to keep those items together until the
53/57 set in the clinic with the plunger-matrix set. This unit is packaged from within a protective container and a formed pouch.
The final pharmacological product assembled consists of the plunger-matrix assembly, which is inserted into the applicator assembly. TDS is activated by compressing the spring and later twisting the plunger to lock and keep the spring compressed in place until use. When activated, the spring supplies the stored energy to the plunger causing it to accelerate and come into contact with the skin. Upon contact with the skin, the microstructures penetrate through the stratum corneum, and hPTH dissolves quickly in the skin. Following the activation of the spring and delivery of hPTH, the device is removed and discarded. The applicator assembly and plunger-matrix assembly, as well as the assembled TDS final product correspond to those shown in FIGS. 4A4B.
EXAMPLE 4
IN VIVO STUDY: HUMAN PARATHYROID HORMONE ADMINISTRATION, hPTH (1 -34), THROUGH A MICROPROJECTION MATRIX DEVICE IN HEALTHY HUMAN BEINGS
An open, single-dose, randomized, 3-way crossover study was performed on 16 healthy female volunteers to determine the pharmacokinetics (along with additional secondary objectives) of 32 pg hPTH (1-34) and 64 pg hPTH (1 -34) (32 pg of hPTH (1-34) x 2) delivered using the microneedle transdermal delivery system identified by the MicroCor® trade name, described in Examples 2 and 3 in relation to hPTH (teriparatide) administered subeutaneously (SC)
4/57 commercially available under the trade name FORTEO ', zu pg. A baby was removed after the first treatment, due to the difficulty in bleeding due to venous spasms. The product described in Examples 2 and 3 is referred to in this example generally as MicroCor '' hPTH (1-34) or simply, MicroCor®.
Subjects received a single dose of 32 pg of hPTH (1-34) or 64 pg of hPTH (1-34) (32 pg x 2), by applying the MicroCor® device to an abdominal site for 5 minutes. Treatment with FORTEO® was performed by administering a subcutaneous injection to the abdominal wall. The treatments were separated by an interval of 48 hours. The plasma sampling scheme was as follows: pre-treatment, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 120, 180, 240, 300, 360 minutes and 24 hours after treatment. Vital signs were monitored before treatment, and at 15 and 30 minutes, and at 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours after treatment. Adverse events were monitored throughout the study.
Additional evaluations included: (i) measurement of anti-PTH antibodies before the first treatment and 2 weeks after the last following treatment, (ii) measurement of serum levels of calcium, phosphorus, albumin and proteins in the pretreatment, and 1, 2 , 3, 4, 5, 8, and 24 hours after treatment, as well as (iii) MicroCor® adherence. The following tables summarize the results of the study.
55/57
Table 4 ~ Ί local skin tolerance
I Symptoms [Observation | MÍCroCOT®] ........... FORTEO®
(N ~ 1 7; 49 applications (N = 16) Bleeding evidence YesNo The49 (100%) 1 (6.3%)15 (93.7%) Application discomfort None Mild Moderate 9 (18.4%)31 (61.2%)10 (20.4%) 10 (62.5%)5 (31.3%)1 (6.3%) Preemotion discomfort (MicoCor · ® only) NonesoftModerate 26 (53.1%)21 (42.9%)2 (4.1%) AT Removal discomfort (MicoCor ® only) Nonesoft 44 (89.8%)5 (10.2%) AT
Table 4 ~ 2. Pharmacokinetic Result
Parameter MicroCor® 32 pg MicroCor® 64 pg FORTEO® AUC / Dose(pg * min / mL * mcg) 220 (n = 15) 229 (n = 16) 429 (n-16) Cmax(pg / mL) 180 (n = 16) 336 (n = 16) 85 (n = 16) Tmax ^(mi nutes) 8.1 (n = 16) 7.4 (n = 16) 26.2 (n = 16) T1 / 2 (minutes) 37.1 (n = 16) 52.0 (n = 16) 52 (n = 16) Time to reach 50% of Cmax (normalized plasma), minutes ~ 20 ~ 20 -90 minutes
The application of hPTH with the MicroCor® device demonstrated good skin tolerability. The effects on the skin were transient and well tolerated, with mild to moderate erythema observed.
In terms of general safety, all treatment regimes were well tolerated. No significant adverse effects or unexpected adverse effects occurred. In fact, there was no difference in the adverse effects related to the total treatment between the application of hPTH through the MicroCor® device and treatment at
6/5 ^
basis of Forteo®. Were not observed variations meaningful series levels; rs of calcium; 0, and none antibody anti-PTH was detected - again, demonstrating yet to general security LratamenLõ the basis of MicroCor® in human subjects. Eats can be seen from partii of the data summarized in Table 4-2 , in relation to the product of Forteo®, The system of
MicroCor® delivery exhibits fast pharmacokinetic properties, such as a lower T _max , a higher C _max , and a lower elimination half-life, t 1/2, compared to a subcutaneous injection of the agent. Absorption of hPTH (1-34) occurred more quickly with the MicroCor® delivery system in relation to the Forteo® product, as illustrated by the higher normalized dose value C _max and the faster T _max values for both treatments with MicroCor ®. The half-life based on administration via the MicroCor® device is shorter than with Forteo®. In addition, application using the MicroCor® device was more effective in achieving the desired pulsatile delivery profile of hPTH (1-34) (ie, rapid together and out of the set after reaching C _max ).
The faster delivery of MicroCor® resulted in faster drug elimination. Based on a graph of plasma concentration (normalized) as a function of time, it can be seen that the time to reach 50% of C _max for treatments based on MicroCor® was approximately 20 minutes for both treatments with 32 and 84 micrograms (that is, based on time to reach a normalized plasma concentration of 0.5). In contrast, the time to reach 50% of Cmax for the
57/57 treatment with Forteo® was about 1.5 hours (90 minutes), with case in time after administration. Thus, ο time to reach 50% of C _max for MicroGor®-based treatments about 4.5 times less than that observed for PTH injected subcutaneously (Forteo ^ j which indicates the remarkably faster elimination of the drug, when administered transdermally from a microneedle matrix as in the MicroCor® system.
Finally, based on a residual analysis of the PTH content 10 of the MicroCor® delivery system after delivery of the drug, it was determined that, on average, about 85% of the drug was delivered from the device (ie 85% delivery efficiency).

权利要求:
Claims (4)
[1]
1. Applicator (10, 310, 400) for a microprojection matrix characterized by the fact that it comprises:
an energy storage element (28, 40, 60) which has a first configuration and a second configuration, in which the application of force to the energy storage element causes it to transition from the first configuration to the second configuration , and where the force required for the energy storage element to transition from the first configuration to the second configuration is lower than the force required for the element to transition from the second configuration to the first configuration, where the first configuration is a first stable configuration and the second configuration is a second stable configuration;
an actuating member (20,314,328,410) that can transmit an external force to the energy storage element, a member supporting microprojection (24, 424) connected to the actuating member and which is manipulated by the energy storage element when it transitions from the first configuration for the second configuration, an external cover (16, 312, 402) with an opening
(18) in which the actuating member fits so sliding, a member in contact with skin (12, 406) understanding an portion that can extend horizontally on the skin, in which the member contact
with the skin is positioned in contact with the outer cover.
Petition 870190122917, of 11/25/2019, p. 11/20
[2]
2/4
2. Applicator according to claim 1, characterized by the fact that the energy storage element has an axis of symmetry and rotational symmetry of n-times for an integer n.
[3]
3. Applicator, according to claim 2, characterized by the fact that the energy storage element makes the transition from the first stable configuration to the second stable configuration by applying
force in the direction of axis of symmetry. 4. Applicator, in a deal with any an of claims 2 or 3, featured by the fact in that the n value is located between 3 and 6. 5. Applicator, in a deal with any an of claims 1 to 4, featured by the fact in that the energy storage element (40, 60) has form usually tapered-conical with grooves starting gives part upper trunk (48, 50, 68, 70), starting gives part lower of the cone trunk (52, 54), or starting of both. 6. Applicator, in a deal with any an of claims 1 to 5, featured by the fact that through application in force to the actuating member the element
energy storage transitions from its first stable configuration, in which it is in contact with the skin contact member, to its second stable configuration in which it is in contact with the external cover.
7. Applicator according to any one of claims 1 to 6, characterized by the fact that the actuating member moves within the outer cover between a first position and a second position, where in the
Petition 870190122917, of 11/25/2019, p. 12/20
3/4 its first position, the drive member extends from an upper surface of the outer cover or is embedded within the outer cover.
8. Applicator according to any one of claims 1 to 7, characterized in that a microprojection matrix is fixed to the microprojection supporting member, the microprojection matrix comprises a base, and the base level of the microprojection matrix is below contact surface with the limb's skin.
skin contact following the drive of member actuator. 9. Applicator, from wake up with any one of claims 1 to 8, characterized by the fact in that the
energy storage element is in mechanical coupling relationship with the member supporting microprojection, when the energy storage element is in its first configuration.
10. Applicator according to claim 1, characterized by the fact that the opening of the outer cover is an elongated opening that has platforms on opposite sides of the opening, the actuating member comprises a generally ring-shaped surface on which the energy storage can be placed, and a surface capable of coupling to the platforms in the opening of the external cover and able to fit through the opening, the energy storage element being located between the actuator element and the external cover, the contact area with the skin being generally ring-shaped and connected to the outer cover,
Petition 870190122917, of 11/25/2019, p. 13/20
[4]
4/4 in which, when the actuating member is coupled to the platforms in the opening, the energy storage element has a first stored energy force, and when, when the actuating member is moved into the opening so that it is no longer attaches to the platforms, the energy storage element releases its stored energy for the transition from the first configuration to the second configuration and thereby moves the actuating member.
11. Applicator, according to claim 10, characterized by the fact that the energy storage element, when coupled with the platforms in the opening, has the first stored energy force due to its compaction.
12. Applicator according to any one of claims 1 to 11, characterized in that it also comprises a safety mechanism (300, 302, 316,
318, 320, 322, 350, 352, 354, 356, 360) to prevent movement of the actuating member in a direction that displaces the microprojection matrix.
13. Applicator according to claim 12, characterized by the fact that the safety mechanism comprises a protective cover (350, 360) over the external cover of the applicator or comprises a pin (302, 318, 322) inserted in the actuating member of an applicator.
14. Device characterized by the fact that it comprises an applicator, as defined in any of claims 1 to 13, and a microprojection matrix comprising an active agent.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US20210187263A1|2021-06-24|Applicators for microneedles

---

RU2674083C2|2018-12-04|Microprojection applicators

---

CN107660138B|2021-09-03|Microneedle system for delivering liquid formulations and method for manufacturing microneedle system

---

JP5553612B2|2014-07-16|Applicator for microneedle array

---

US7628781B2|2009-12-08|Medical usage connector assembly for the transfer of fluids

---

BRPI0916150B1|2019-09-24|Hollow microneedle arrangement

---

CN105073180A|2015-11-18|Microneedle applicator comprising a counter assembly

---

BR112020007566A2|2020-09-24|applicator to apply a microneedle matrix to the skin

---

CN209075839U|2019-07-09|A kind of integration transdermal delivery device based on drug storage and micropin

---

JP3425469B2|2003-07-14|Jet injection transdermal absorption device

---

BR112020011356A2|2020-11-17|high-density microneedle

---

JP2016518928A|2016-06-30|Transdermal administration device and transdermal administration method

---

BR112015014969B1|2021-12-07|MICROSTRUCTURE APPARATUS AND METHOD OF MANUFACTURING A MICROSTRUCTURE APPARATUS

同族专利:

---

公开号 | 公开日

---

US20110276027A1|2011-11-10|

---

KR20130112698A|2013-10-14|

---

JP2013525078A|2013-06-20|

---

ZA201209035B|2014-02-26|

---

MX2012012815A|2013-03-05|

---

CA2801247C|2018-09-04|

---

JP5968875B2|2016-08-10|

---

CN102971038A|2013-03-13|

---

US10946180B2|2021-03-16|

---

IL222803D0|2012-12-31|

---

ES2734560T3|2019-12-10|

---

AU2011248166A1|2013-01-10|

---

EP2566568B1|2019-04-10|

---

EP2566568A4|2014-04-16|

---

KR101808635B1|2017-12-13|

---

US9687640B2|2017-06-27|

---

CA2801247A1|2011-11-10|

---

US20210187263A1|2021-06-24|

---

US20170361079A1|2017-12-21|

---

AU2011248166B2|2015-12-17|

---

MX351458B|2017-10-16|

---

WO2011140240A2|2011-11-10|

---

BR112012028263A2|2016-11-01|

---

IL222803A|2016-05-31|

---

RU2012151843A|2014-06-10|

---

EP2566568A2|2013-03-13|

---

RU2569029C2|2015-11-20|

---

WO2011140240A3|2012-03-01|

---

CN105662530A|2016-06-15|

---

CN105662530B|2018-07-20|

---

CN102971038B|2016-02-03|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3964482A|1971-05-17|1976-06-22|Alza Corporation|Drug delivery device|

---

AT406935T|1997-12-11|2008-09-15|Alza Corp|DEVICE FOR IMPROVING THE TRANSDERMAL RIVER OF MEDICAMENTS|

---

US6312612B1|1999-06-09|2001-11-06|The Procter & Gamble Company|Apparatus and method for manufacturing an intracutaneous microneedle array|

---

US6743211B1|1999-11-23|2004-06-01|Georgia Tech Research Corporation|Devices and methods for enhanced microneedle penetration of biological barriers|

---

EP1239916B1|1999-12-10|2005-11-23|ALZA Corporation|Device and method for enhancing microprotrusion skin piercing|

---

US6537242B1|2000-06-06|2003-03-25|Becton, Dickinson And Company|Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance|

---

MXPA03003299A|2000-10-13|2004-12-13|Johnson & Johnson|Apparatus and method for piercing skin with microprotrusions.|

---

DE60111771T2|2000-10-13|2006-05-04|Alza Corp., Mountain View|MIKROKLINGEANORDUNGSAUFPRALLAPPLIKATOR|

---

AU9681701A|2000-10-13|2002-04-22|Alza Corp|Microprotrusion member retainer for impact applicator|

---

EP1333880B1|2000-10-26|2009-04-15|Alza Corporation|Transdermal drug delivery devices having coated microprotrusions|

---

HU0402605A2|2001-12-20|2005-06-28|Alza Corporation|Skin-piercing microprojections having piercing depth control|

---

CN100553710C|2002-02-04|2009-10-28|贝克顿·迪金森公司|The apparatus and method of percutaneous transmission or extraction of substance|

---

CN100571643C|2003-10-31|2009-12-23|阿尔扎公司|The self-driven applicator that is used for microprotrusion array|

---

EP1706171A1|2003-12-29|2006-10-04|3M Innovative Properties Company|Medical devices and kits including same|

---

WO2007001430A2|2004-10-22|2007-01-04|U.S. Department Of Veterans Affairs|Disimmortalizable mammalian chromaffin cell lines for cell therapy for pain|

---

EP1833547A1|2004-11-18|2007-09-19|3M Innovative Properties Company|Low-profile microneedle array applicator|

---

US9174035B2|2004-11-18|2015-11-03|3M Innovative Properties Company|Microneedle array applicator and retainer|

---

JP2008520367A|2004-11-18|2008-06-19|スリーエムイノベイティブプロパティズカンパニー|Non-skin-type microneedle array applicator|

---

US20060253078A1|2005-04-25|2006-11-09|Wu Jeffrey M|Method of treating skin disorders with stratum corneum piercing device|

---

US20080195035A1|2005-06-24|2008-08-14|Frederickson Franklyn L|Collapsible Patch and Method of Application|

---

EP2474338B1|2005-06-27|2013-07-24|3M Innovative Properties Company|Microneedle array applicator device|

---

CA2613114C|2005-06-27|2015-02-24|3M Innovative Properties Company|Microneedle cartridge assembly and method of applying|

---

CA2620943A1|2005-09-02|2007-03-08|Iomai Corporation|Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof|

---

US7658728B2|2006-01-10|2010-02-09|Yuzhakov Vadim V|Microneedle array, patch, and applicator for transdermal drug delivery|

---

WO2007124411A1|2006-04-20|2007-11-01|3M Innovative Properties Company|Device for applying a microneedle array|

---

US8821446B2|2007-01-22|2014-09-02|Corium International, Inc.|Applicators for microneedles|

---

ES2817249T3|2007-04-16|2021-04-06|Corium Inc|Microneedle matrices obtained by dissolution and casting containing an active principle|

---

US8911749B2|2007-04-16|2014-12-16|Corium International, Inc.|Vaccine delivery via microneedle arrays|GB0402131D0|2004-01-30|2004-03-03|Isis Innovation|Delivery method|

---

ES2817249T3|2007-04-16|2021-04-06|Corium Inc|Microneedle matrices obtained by dissolution and casting containing an active principle|

---

US8911749B2|2007-04-16|2014-12-16|Corium International, Inc.|Vaccine delivery via microneedle arrays|

---

CA2745339C|2007-12-24|2016-06-28|The University Of Queensland|Coating method|

---

JP6078230B2|2009-03-02|2017-02-08|セブンス センス バイオシステムズ，インコーポレーテッド|Techniques and devices related to blood sampling|

---

US9041541B2|2010-01-28|2015-05-26|Seventh Sense Biosystems, Inc.|Monitoring or feedback systems and methods|

---

US9033898B2|2010-06-23|2015-05-19|Seventh Sense Biosystems, Inc.|Sampling devices and methods involving relatively little pain|

---

WO2012006677A1|2010-07-14|2012-01-19|The University Of Queensland|Patch applying apparatus|

---

WO2012018486A2|2010-07-26|2012-02-09|Seventh Sense Biosystems, Inc.|Rapid delivery and/or receiving of fluids|

---

US20120039809A1|2010-08-13|2012-02-16|Seventh Sense Biosystems, Inc.|Systems and techniques for monitoring subjects|

---

US9017289B2|2010-11-03|2015-04-28|Covidien Lp|Transdermal fluid delivery device|

---

EP3087919B1|2011-04-29|2018-09-26|Seventh Sense Biosystems, Inc.|Receiving fluids|

---

US9295417B2|2011-04-29|2016-03-29|Seventh Sense Biosystems, Inc.|Systems and methods for collecting fluid from a subject|

---

EP3235429A1|2011-04-29|2017-10-25|Seventh Sense Biosystems, Inc.|Systems and methods for collection and/or manipulation of blood spots or other bodily fluids|

---

DK2641614T3|2011-06-28|2021-03-29|Labo Juversa Co Ltd|Pharmaceutical preparation integrated with microneedles for skin treatment|

---

JP6265740B2|2011-10-06|2018-01-24|久光製薬株式会社|applicator|

---

WO2013053022A1|2011-10-12|2013-04-18|The University Of Queensland|Delivery device|

---

AU2015227524B2|2011-10-12|2017-05-18|Kindeva Drug Delivery L.P.|Integrated microneedle array delivery system|

---

EP2766067B1|2011-10-12|2020-04-22|3M Innovative Properties Company|Integrated microneedle array delivery system|

---

AU2015227515B2|2011-10-12|2017-05-18|Kindeva Drug Delivery L.P.|Integrated microneedle array delivery system|

---

WO2013082427A1|2011-11-30|2013-06-06|3M Innovative Properties Company|Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same|

---

US20130158468A1|2011-12-19|2013-06-20|Seventh Sense Biosystems, Inc.|Delivering and/or receiving material with respect to a subject surface|

---

ES2761255T3|2012-04-05|2020-05-19|Hisamitsu Pharmaceutical Co|Lancing device|

---

EP2662110A1|2012-05-10|2013-11-13|Debiotech S.A.|Device and method for inserting needles|

---

JP5903016B2|2012-06-27|2016-04-13|コスメディ製薬株式会社|Protective release sheet for microneedle patch|

---

WO2014058746A1|2012-10-10|2014-04-17|3M Innovative Properties Company|Force-controlled applicator for applying a microneedle device to skin|

---

US10300260B2|2012-10-10|2019-05-28|3M Innovative Properties Company|Applicator and method for applying a microneedle device to skin|

---

CN104797287B|2012-11-16|2017-12-26|3M创新有限公司|Power control application device|

---

KR102265808B1|2012-12-21|2021-06-16|코리움, 인크.|Microarray for delivery of therapeutic agent and methods of use|

---

JP6158838B2|2012-12-21|2017-07-05|久光製薬株式会社|applicator|

---

RU2622605C2|2013-02-28|2017-06-16|Кимберли-Кларк Ворлдвайд, Инк.|Device for transdermal drug delivery|

---

US10245422B2|2013-03-12|2019-04-02|Corium International, Inc.|Microprojection applicators and methods of use|

---

EP2968116A1|2013-03-15|2016-01-20|Corium International, Inc.|Microarray with polymer-free microstructures, methods of making, and methods of use|

---

WO2014150285A2|2013-03-15|2014-09-25|Corium International, Inc.|Multiple impact microprojection applicators and methods of use|

---

JP2016512754A|2013-03-15|2016-05-09|コリウム インターナショナル， インコーポレイテッド|Microarray, method of use and manufacturing for delivery of therapeutic agents|

---

AU2014233695A1|2013-03-15|2015-10-01|Corium International, Inc.|Microarray for delivery of therapeutic agent and methods of use|

---

KR101712413B1|2013-03-22|2017-03-06|쓰리엠 이노베이티브 프로퍼티즈 컴파니|Microneedle applicator comprising a counter assembly|

---

EP3003458B1|2013-05-31|2019-12-04|3M Innovative Properties Company|Microneedle injection apparatus comprising a dual cover|

---

CN105263562B|2013-05-31|2018-09-21|3M创新有限公司|Microneedle injection and infusion apparatus and its application method|

---

MX353241B|2013-05-31|2018-01-05|3M Innovative Properties Co|Microneedle injection apparatus comprising an inverted actuator.|

---

EP3027263A1|2013-07-30|2016-06-08|ZP Opco, Inc.|Low-profile microneedle patch applicator|

---

EP3067088B1|2013-11-05|2019-09-04|Hisamitsu Pharmaceutical Co., Inc.|Applicator|

---

CN103654969B|2013-12-24|2015-12-30|湖州美奇医疗器械有限公司|A kind of medical treatment helps pin device|

---

US20170181822A1|2014-03-10|2017-06-29|3M Innovative Properties Company|Micro-needle device|

---

EP3117867B1|2014-03-12|2019-07-24|Labo Juversa Co., Ltd.|Micro-needle preparation administration member for intradermal placement of target substance and apparatus for rapid administration of micro-needle preparation|

---

EP3137154B1|2014-04-30|2019-09-04|Sorrento Therapeutics, Inc.|Cartridge portion of transdermal drug delivery apparatus|

---

AU2015308618B2|2014-08-29|2021-05-20|Corium, Inc.|Microstructure array for delivery of active agents|

---

EP3188714A1|2014-09-04|2017-07-12|Corium International, Inc.|Microstructure array, methods of making, and methods of use|

---

AU2016214968B2|2015-02-02|2021-02-25|Vaxxas Pty Limited|Microprojection array applicator and method|

---

CN106456954A|2015-02-13|2017-02-22|美德阿利克斯株式会社|Microneedle insertion device and microneedle patch application device|

---

EP3395397A4|2015-12-21|2019-07-03|Medrx Co., Ltd.|Microneedle patch applicator and housing for same|

---

WO2016162449A1|2015-04-07|2016-10-13|Lts Lohmann Therapie-Systeme Ag|Microneedle system for administering liquid formulations|

---

US10857093B2|2015-06-29|2020-12-08|Corium, Inc.|Microarray for delivery of therapeutic agent, methods of use, and methods of making|

---

US10828480B2|2015-09-02|2020-11-10|Hisamitsu Pharmaceutical Co., Inc.|Applicator|

---

WO2017045031A1|2015-09-18|2017-03-23|Vaxxas Pty Limited|Microprojection arrays with microprojections having large surface area profiles|

---

EP3851153A1|2016-04-29|2021-07-21|Sorrento Therapeutics, Inc.|Microneedle array assembly, drug delivery device and method for administering liquid across a broad area at low pressure|

---

CN113975620A|2016-12-16|2022-01-28|索伦托治疗有限公司|Fluid delivery device and method of assembling same|

---

CA3047282A1|2016-12-16|2018-06-21|Sorrento Therapeutics, Inc.|Method for administering a medicament suitable for treating a migraine or cluster headache|

---

KR20190088073A|2016-12-16|2019-07-25|소렌토 쎄라퓨틱스, 인코포레이티드|Attachment band for fluid delivery device and method of using same|

---

CN110312546A|2016-12-16|2019-10-08|索伦托治疗有限公司|Application mechanism and its application method for fluid delivery device|

---

CN110709250A|2017-03-31|2020-01-17|瓦克萨斯私人有限公司|Apparatus and method for coating a surface|

---

WO2018227246A1|2017-06-13|2018-12-20|Vaxxas Pty Limited|Quality control of substrate coatings|

---

US20200368511A1|2017-08-04|2020-11-26|Vaxxas Pty Limited|Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches |

---

CA3073835A1|2017-08-30|2019-03-07|Pirouette Medical LLC|Compact auto-injector|

---

WO2019071129A1|2017-10-05|2019-04-11|Pirouette Medical LLC|Protective case for an auto-injector|

---

EP3810388A1|2018-06-25|2021-04-28|Corium, Inc.|Hybrid method of forming microstructure array molds, methods of making microstructure arrays, and methods of use|

---

JP1632957S|2018-10-30|2019-06-03|

---

DE102019200557A1|2019-01-17|2020-07-23|Lts Lohmann Therapie-Systeme Ag|Applicator|

---

DE102019200563A1|2019-01-17|2020-07-23|Lts Lohmann Therapie-Systeme Ag|Applicator|

---

WO2021141304A2|2020-01-09|2021-07-15|연세대학교 산학협력단|Microneedle applicator|

法律状态:
2018-12-26| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-08-27| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-02-11| B25D| Requested change of name of applicant approved|Owner name: CORIUM, INC. (US) |

---

2020-03-31| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-06-02| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US33117510P| true| 2010-05-04|2010-05-04|

---

US61/331,175|2010-05-04|

---

PCT/US2011/035221|WO2011140240A2|2010-05-04|2011-05-04|Applicators for microneedles|

---